Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization

Molecular Immunology

Volumn 57, Issue 2, 2014, Pages 191-199

  Saenz, R ^a   Messmer, B ^a   Futalan, D ^a   Tor, Y ^b   Larsson, M ^c   Daniels, G ^a   Esener, S ^a,b   Messmer, D ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Adjuvant; Dendritic cells; Immune response; Peptide

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; HP91 VACCINE; MALEIMIDE; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; CONTROLLED STUDY; DENDRITIC CELL; DIMERIZATION; DRUG ACTIVITY; DRUG CONJUGATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ADJUVANT; DENDRITIC CELLS; IMMUNE RESPONSE; PEPTIDE;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HMGB1 PROTEIN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALEIMIDES; MELANOMA; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; TH1 CELLS;

EID: 84886431329     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.09.007     Document Type: Article

References (39)

1. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449(7161):419-426.
2. Dubensky T.W., Reed S.G. Adjuvants for cancer vaccines. Semin. Immunol. 2010.
3. Saenz R., Souza Cda S., Huang C.T., Larsson M., Esener S., Messmer D. HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen. Vaccine 2010, 28(47):7556-7562. PMCID: 2963688.
4. Agresti A., Bianchi M.E. HMGB proteins and gene expression. Curr. Opin. Genet. Dev. 2003, 13(2):170-178.
5. Rovere-Querini P., Capobianco A., Scaffidi P., Valentinis B., Catalanotti F., Giazzon M., et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004, 5(8):825-830.
6. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418(6894):191-195.
7. Ulloa L., Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 2006, 17(3):189-201.
8. Wang H., Vishnubhakat J.M., Bloom O., Zhang M., Ombrellino M., Sama A., et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999, 126(2):389-392.
9. Messmer D., Yang H., Telusma G., Knoll F., Li J., Messmer B., et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 2004, 173(1):307-313.
10. Telusma G., Datta S., Mihajlov I., Ma W., Li J., Yang H., et al. Dendritic cell activating peptides induce distinct cytokine profiles. Int. Immunol. 2006, 18(11):1563-1573.
11. Yang H., Hreggvidsdottir H.S., Palmblad K., Wang H., Ochani M., Li J., et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(26):11942-11947. PMCID: 2900689.
12. Hoppe G., Talcott K.E., Bhattacharya S.K., Crabb J.W., Sears J.E. Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1. Exp. Cell Res. 2006, 312(18):3526-3538.
13. Yang H., Lundback P., Ottosson L., Erlandsson-Harris H., Venereau E., Bianchi M.E., et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 2012, 18:250-259. PMCID: 3324950.
14. Thomas J.O., Travers A.A. HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem. Sci. 2001, 26(3):167-174.
15. Bienkiewicz E.A., Moon Woody A., Woody R.W. Conformation of the RNA polymerase II C-terminal domain: circular dichroism of long and short fragments. J. Mol. Biol. 2000, 297(1):119-133.
16. van Holst G.J., Fincher G.B. Polyproline II confirmation in the protein component of arabinogalactan-protein from lolium multiflorum. Plant Physiol. 1984, 75(4):1163-1164. PMCID: 1067069.
17. Li S.C., Goto N.K., Williams K.A., Deber C.M. Alpha-helical, but not beta-sheet, propensity of proline is determined by peptide environment. Proc. Natl. Acad. Sci. U.S.A. 1996, 93(13):6676-6681. PMCID: 39085.
18. Sonnichsen F.D., Van Eyk J.E., Hodges R.S., Sykes B.D. Effect of trifluoroethanol on protein secondary structure: an NMR and CD study using a synthetic actin peptide. Biochemistry 1992, 31(37):8790-8798.
19. Jenne L., Arrighi J.F., Jonuleit H., Saurat J.H., Hauser C. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res. 2000, 60(16):4446-4452.
20. Yu H., Chen J.K., Feng S., Dalgarno D.C., Brauer A.W., Schreiber S.L. Structural basis for the binding of proline-rich peptides to SH3 domains. Cell 1994, 76(5):933-945.
21. Singh M., O-Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 1999, 17(11):1075-1081.
22. McCluskie M.J., Weeratna R.D. Novel Adjuvant Syst. 2001, 1(3):263-271.
23. Jin M.S., Lee J.O. Structures of the toll-like receptor family and its ligand complexes. Immunity 2008, 29(2):182-191.
24. Nunez Miguel R., Wong J., Westoll J.F., Brooks H.J., O'Neill L.A., Gay N.J., et al. A dimer of the Toll-like receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins. PLoS One 2007, 2(8):e788. PMCID: 1945083.
25. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 1995, 270(43):25752-25761.
26. Dumitriu I.E., Baruah P., Bianchi M.E., Manfredi A.A., Rovere-Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol. 2005, 35(7):2184-2190.
27. Park J.S., Gamboni-Robertson F., He Q., Svetkauskaite D., Kim J.Y., Strassheim D., et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 2006, 290(3):C917-C924.
28. Park J.S., Svetkauskaite D., He Q., Kim J.Y., Strassheim D., Ishizaka A., et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 2004, 279(9):7370-7377.
29. van Zoelen M.A., Yang H., Florquin S., Meijers J.C., Akira S., Arnold B., et al. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products (Rage) in Hmgb1 induced inflammation in vivo. Shock 2008.
30. Yu M., Wang H., Ding A., Golenbock D.T., Latz E., Czura C.J., et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26(2):174-179.
31. Ivanov S., Dragoi A.M., Wang X., Dallacosta C., Louten J., Musco G., et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007, 110(6):1970-1981. PMCID: 1976374.
32. Orlova V.V., Choi E.Y., Xie C., Chavakis E., Bierhaus A., Ihanus E., et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 2007, 26(4):1129-1139. PMCID: 1852832.
33. Rauvala H., Rouhiainen A. Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim. Biophys. Acta 2010, 1799(1-2):164-170.
34. Salmivirta M., Rauvala H., Elenius K., Jalkanen M. Neurite growth-promoting protein (amphoterin, p30) binds syndecan. Exp. Cell Res. 1992, 200(2):444-451.
35. Milev P., Chiba A., Haring M., Rauvala H., Schachner M., Ranscht B., et al. High affinity binding and overlapping localization of neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta with tenascin-R, amphoterin, and the heparin-binding growth-associated molecule. J. Biol. Chem. 1998, 273(12):6998-7005.
36. Chen G.Y., Tang J., Zheng P., Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009, 323(5922):1722-1725. PMCID: 2765686.
37. Patel A., Dong J.C., Trost B., Richardson J.S., Tohme S., Babiuk S., et al. Pentamers not found in the universal proteome can enhance antigen specific immune responses and adjuvant vaccines. PLoS One 2012, 7(8):e43802. PMCID: 3427150.
38. Pujals S., Giralt E. Proline-rich, amphipathic cell-penetrating peptides. Adv. Drug Deliv. Rev. 2008, 60(4-5):473-484.
39. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 2004, 4(6):469-478.